¹Ù·Î°¡±â ¸Þ´º

¹Ù·Î°¡±â ¸Þ´º º»¹®³»¿ë ¹Ù·Î°¡±â ¸ÞÀθ޴º ¹Ù·Î°¡±â

ÁÖ¿ä¾È³»

HOME »çÀÌÆ®¸Ê

FONT SIZE

ÆùƮũ±â Å°¿ò 100% 110% 120% 130% 140% ÆùƮũ±â ÁÙÀÓ
¸Þ´ºº¸±â
 
Á¦¸ñ
11/20 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
ÀÛ¼ºÀÏ
2021-11-19
Á¶È¸¼ö
217


¾È³çÇϼ¼¿ä ö±ÕÀÔ´Ï´Ù. 

À̹øÁÖ Åä¿äÀÏ¿¡ Á¦°¡ ¹ßÇ¥µå¸± ³í¹®ÀÇ Á¦¸ñÀº 
"A lysosome-targeted DNA nanodevice selectively targets macrophages to attenuate tumours" À̸ç 
Áö³­ÁÖ¿¡ (2021.11.11.) Nature nanotechnology¿¡ ÃâÆǵǾú½À´Ï´Ù. 
ÀÌÀü¿¡µµ ´Ù¾çÇÑ ³í¹® ¹ßÇ¥¿Í, ½ºÅ͵ð ¹ßÇ¥¿¡¼­ DC¿Í MacrophageÀÇ À¯»ç¼º°ú, Â÷ÀÌÁ¡À» À̾߱âÇϸ鼭, 
Macrophage°¡ °®°í ÀÖ´Â ³ôÀº phagosomal activity¸¦ Á¦¾îÇÏ°Ô µÇ¸é DC ó·¯ cross-presentationÀ» ÀßÇÏ´Â ¹æ½ÄÀ¸·Î À¯µµ¸¦ ÇÒ ¼ö ÀÖ´Â
°¡´É¼º¿¡ ´ëÇؼ­ ¸»¾¸À» µå¸°ÀûÀÌ ÀÖ½À´Ï´Ù. 
À̹ø ³í¹®Àº Á¤È®È÷ ±×·±Á¡À» ÀÌ¿ëÇÏ¿©, Tumor site¿¡ ´Ù¼ö Á¸ÀçÇϸç, TumorÀÇ ¼ºÀåÀ» µ½±âµµÇÏ´Â M2 macrophage¸¦ Ÿ°ÙÀ¸·Î ÇÏ¿©
¿ÀÈ÷·Á cross-presentation Çϵµ·Ï À¯µµÇÏ¿© tumor¸¦ Á¦¾îÇÏ´Â °ÍÀ» º¸¿©ÁØ ³í¹®ÀÔ´Ï´Ù. 
Åä¿äÀÏ¿¡ ºËµµ·Ï ÇÏ°Ú½À´Ï´Ù. 
°¨»çÇÕ´Ï´Ù. 

³í¹® ¸µÅ© : https://www.nature.com/articles/s41565-021-00988-z
 
÷ºÎÆÄÀÏ:
÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.
´ÙÀ½±Û
11/27 ¹ßÇ¥³í¹® ÀÔ´Ï´Ù
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä. À̹øÁÖ ¹ßÇ¥ÀÚ ¿µÁø ÀÔ´Ï´Ù. Á¦°¡ ¼±Á¤ÇÑ ³í¹®Àº 2019³âµµ¿¡ Cell reports¿¡ ÃâÆÇ µÈ " TNFR2 Signaling Enhances ILC2 Survival, Function, and Induction of Airway Hyperreactivity" ÀÔ´Ï´Ù. º» ¿¬±¸¸¦ ÅëÇØTNF/TNFR2 axis°¡ Group 2 innate lymphoid cell (ILC2)ÀÇ immune check poin..
ÀÌÀü±Û
11/20 ¹ßÇ¥³í¹® ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ´ÙÁ¤ÀÔ´Ï´Ù. Á¦°¡ À̹ø¿¡ ¼±Á¤ÇÑ ³í¹®Àº 2018³â Cell reports¿¡ ÃâÆǵÈ, 'Suppression of Tcf1 by inflammatory cytokines facilitates effector CD8 T cell differentiation'ÀÔ´Ï´Ù. À§ ³í¹®Àº transcription factorÀÎ Tcf1ÀÇ ¹ßÇöÀÌ T cellÀÇ effector differentiation¿¡ ¾î¶°ÇÑ..